

ITOC-1 Programme

Wednesday 12 March 2014

Satellite Symposium: Is the immuno-oncology the next new paradigm in cancer treatments?

11:00 - 12:30

Auditorium

Chair: P. Romero (Switzerland)

Chair: P.A. Ascierto (Italy)

11:00 **Introduction**

11:05 **Cancer evasion of the immune system: the fundamentals**

Speaker: P. Romero (Switzerland)

11:25 **Checkpoint blockade a concept or already a reality?**

Speaker: P.A. Ascierto (Italy)

11:50 **Emerging pathways**

Speaker: C. Holler (Austria)

12:15 **Conclusions and Q and A**

Plenary Session: Opening Plenary Session

13:00 - 15:00

Auditorium

Chair: H. Zwierzina (Austria)

Chair: V. Nussler (Germany)

13:00 **Welcome address**

Speaker: H. Zwierzina (Austria)

13:10 **KEYNOTE LECTURE: Cancer immunotherapy-current and future advancements**

S1

Speaker: A.M.M. Eggermont (France)

13:40 **Combinatorial Immunotherapy and Anti-angiogenic Approaches in Ovarian Cancer**

Speaker: L. Kandalaft (Switzerland)

14:00	Toll like receptor 7 agonists and ligands for RIG-I for cancer immunotherapy Speaker: S. Endres (Germany)	S3
14:20	Molecular pathways associated with immune modulation and thalidomide analogues Speaker: R. Chopra (USA)	S4
14:40	Proffered Paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: Clinical and immunological predictive pretreatment factors of activity in the IMPACT trial Speaker: H.J. Schmoll (Germany)	S5
14:50	Proffered Paper: Anti-tumour immunomodulatory activity of heat shock protein Hsp70 in therapy of malignant brain tumours: Preclinical and clinical data Speaker: M. Shevtsov (Russian Federation)	S6

Plenary Session: Cancer Immunology

15:30 - 17:10 Auditorium

	Chair: T. Gajewski (USA)	
	Chair: P. Romero (Switzerland)	
15:30	KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells Speaker: C. Maccalli (Italy)	S7
16:00	Bavituximab: A novel phosphatidylserine-targeting immunotherapy for the treatment of cancer Speaker: J. Shan (USA)	S8
16:20	Targeting the myeloma microenvironment with immunotherapy Speaker: I. Borrello (USA)	
16:40	BiTe antibodies: from ex vivo models to clinical application in solid tumours Speaker: P. Kufer (Germany)	
17:00	Proffered Paper: Identification of novel immune checkpoints as targets for cancer immunotherapy Speaker: G. Cojocaru (Israel)	S9

Poster Session: Monitoring of Immunotherapy


17:15 - 18:45

- Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model** P10
 Poster: C. Bauer (Germany)
- Developing an immunotherapy strategy for the effective treatment of patients with non small cell lung cancer (NSCLC): Strategies to evaluate immunity in patients on clinical trials** P11
 Poster: M. Neuberger (Germany)
- Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses** P12
 Poster: S. Pellegatta (Italy)
- Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)** P13
 Poster: M. Kowanetz (USA)

Poster Session: Immunomodulation

17:15 - 18:45

- Cell-based gene delivery leverages conventional immunotherapy for cancer** P14
 Poster: C. Gunther (Germany)
- A genetic mouse model to identify the role of the immune adapter protein MyD88 in colorectal cancer** P15
 Poster: A. Holtorf (Germany)
- Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: A potential mechanism for the NK cell-based immunotherapy efficacy** P16
 Poster: G. Sconocchia (Italy)
- RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells** P17
 Poster: M. Schnurr (Germany)



P18

The tumour leukocyte infiltrate is the key predictor for therapeutic response to catumaxomab therapy

Poster: B. Mayer (Germany)

Immunomodulation of blasts in AML-Patients (pts) with clinically approved response modifiers to improve antileukaemic T-cell reactivity: An ex vivo simulation of the clinical situation

Poster: H. Schmetzer (Germany)

P19

Lack of T cell exhaustion in acute myeloid leukaemia

Poster: F. Schnorfeil (Germany)

P20

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention

Poster: P. Prinz (Germany)

P21

Immunomodulation induced by resveratrol or genistein on proliferation and apoptosis of tumour colon cells

Poster: L.I. Brasoveanu (Romania)

P22

Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors

Poster: G. Fey (Germany)

P23

Aviscumine enhances NK- cytotoxicity against tumor cells

Poster: G. Gamerith (Austria)

P24

Poster Session: Other

17:15 - 18:45

Access to diagnostics: A bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

Poster: K. Lykopoulos (United Kingdom)

P25

Cancer associated fibroblasts contribute to the immune suppression of breast cancer by augmentation of the inflammatory products

Poster: L. Langroudi (Iran)

P26

Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients

Poster: S. Eketorp Sylvan (Sweden)

P27

Efficient CD19-positive leukaemia cell lysis mediated by a T cell-recruiting triplebody a[19-3-19]

Poster: C. Roskopf (Germany)

P28

	P29
T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors Poster: S.R. Hadrup (Denmark)	
The use of HER2 receptors status as a prognostic index for estrogen receptor positive breast cancer patients Poster: A. Tawfeek (Iraq)	P30
Genomic profiling and functional characterisation of a new myeloid cell type enriched in renal cell carcinoma Poster: D. Brech (Germany)	P31
High resolution mass spectrometry reveals the depth and diversity of HLA-I peptidomes Poster: M. Bassani-Sternberg (Germany)	P32
NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells Poster: H. Klingemann (USA)	P33

Thursday 13 March 2014

Plenary Session: Targeting Immune Suppression

08:30 - 10:00		Auditorium
<hr/>		
	Chair: D.J. Schendel (Germany)	
	Chair: S. Khleif (USA)	
08:30	KEYNOTE LECTURE: Regulatory T cells and suppression of immune response Speaker: J.P. Allison (USA)	S34
09:00	Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment Speaker: T. Gajewski (USA)	S2
09:20	Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4 Speaker: P. Sharma (USA)	S35
09:40	Inhibition of indoleamine-2,3-dioxygenase (IDO)- mediated tumour immune escape Speaker: C. Opitz (Germany)	S37

Plenary Session: Stimulation of Immune Function

10:30 - 12:10

Auditorium

- Chair: L. Zitvogel (France)
 Chair: A. Dalglish (United Kingdom)
- 10:30 **Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response** S38
 Speaker: A. Dalglish (United Kingdom)
- 10:50 **Role of gut microbiota in the anticancer effects of cytotoxic drugs** S39
 Speaker: L. Zitvogel (France)
- 11:10 **Rationales, current and future for combination of immunooncology therapies**
 Speaker: A. Korman (USA)
- 11:30 **Oncolytic herpes simplex virus encoding GM-CSF for melanoma therapy** S40
 Speaker: M. Urosevic-Maiwald (Switzerland)
- 11:50 **Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer** S41
 Speaker: C. Klein (Switzerland)

Satellite Symposium: Cancer immunotherapy: changing treatment paradigms in oncology

13:00 - 14:00

Auditorium

- 13:00 **Welcome and Introduction**
 Chair: I. Melero (USA)
- 13:10 **Exploring the evolving landscape of cancer immunotherapy**
 Speaker: I. Melero (USA)
- 13:25 **From innovative science to clinical trials**
 Speaker: E. Cha (USA)
- 13:40 **Future approaches to cancer immunotherapy**
 Speaker: C. Klein (Switzerland)
- 13:55 **Close**
 Chair: I. Melero (USA)

Plenary Session: Therapeutic Anti-Cancer Vaccines

14:00 - 15:30

Auditorium

	Chair: D.J. Schendel (Germany)	
	Chair: S. Endres (Germany)	
14:00	KEYNOTE LECTURE: Vaccine development Speaker: S. Khleif (USA)	S42
14:30	Dendritic cell vaccination combined with CTLA4 blockade Speaker: K. Thielemans (Belgium)	S43
14:50	Role of CD40 activation in anti-tumour vaccine efficacy Speaker: C.J.M. Melief (Netherlands)	S44
15:10	mRNA-based cancer vaccines Speaker: K. Kallen (Germany)	S45

Plenary Session: Monitoring of Immunotherapy

16:00 - 17:30

Auditorium

	Chair: L. Hakansson (Sweden)	
	Chair: B. Fox (USA)	
16:00	Immune response parameters Speaker: L. Hakansson (Sweden)	S46
16:20	Tumour infiltrating lymphocytes - a predictive marker? Speaker: J. Galon (France)	S47
16:40	Biomarker development for ipilimumab and prostate GVAX treatment Speaker: T. De Gruijl (Netherlands)	S48
17:00	Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A Speaker: E. Cha (USA)	S49
17:20	Proffered Paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics Speaker: H. Layman (USA)	S50

Poster Session: Vaccines

17:30 - 19:00

Identification of prostate cancer-associated antigens by oxygen manipulation	P51
Poster: T. Ma (USA)	
A new pathway of tumour antigen loading of human dendritic cells via intercellular communication	P52
Poster: G. Penna (Italy)	
Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma	P53
Poster: J. Kovacs (Germany)	
Possible role of MDSC for the induction of tumour-specific T cells following LRAST	P54
Poster: P. Rose (Germany)	
Dendritic cell vaccination for postremission therapy in AML	P55
Poster: F. Lichtenegger (Germany)	
A novel cancer vaccine with nanogel-based antigen transporter and sequence-optimised long peptide antigen	P56
Poster: N. Harada (Japan)	
Activation of RIG-I induces immunogenic cell death	P57
Poster: S. Bek (Germany)	

Poster Session: Immunocytokines

17:30 - 19:00

Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer	P58
Poster: S. Jallad (United Kingdom)	

Poster Session: Combination therapy

17:30 - 19:00

Depleting the suppressors for the benefit of immunotherapy against cervical cancer	P59
Poster: O. Draghiciu (Netherlands)	
Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells	P60
Poster: K. Martin (Switzerland)	
Evaluation of p21 promoter for radiation induced transcriptional targeting of interleukin 12 gene therapy	P61
Poster: U. Kamensek (Slovenia)	
Effetiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines	P62
Poster: G. Bottaro Gelaleti (Brazil)	

Poster Session: Adoptive Immunotherapy

17:30 - 19:00

Autologous tumour cells and SW742 allogeneic cell line have comparable stimulating effect on PBMCs of gastrointestinal malignant patients in vitro	P63
Poster: A. Sheikhi (Iran)	
T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma	P64
Poster: C. Dargel (Germany)	
Minor-histocompatibility-antigen UTY as target for graft-versus-leukaemia and graft-versus-haematopoiesis in the canine-model	P65
Poster: D. Bund (Germany)	
Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy	P66
Poster: S. Schmied (Germany)	
Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)	P67
Poster: H. Specht (Germany)	

Poster Session: Engineered T-cell therapy

17:30 - 19:00

A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model	P68
Poster: S. Kobold (Germany)	
Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias	P69
Poster: R. Klar (Germany)	
Development of clinically implementable imaging strategies for tracking T cell receptor-transgenic T cells	P70
Poster: S. Mall (Germany)	
Adoptive transfer of TCR gene-transduced lymphocytes targeting MAGE-A4 for refractory esophageal cancer	P71
Poster: H. Shiku (Japan)	
Transgenic expression of a chimeric signaling receptor to facilitate T cell costimulation in the tumour environment	P72
Poster: R. Schlenker (Germany)	
Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes	P73
Poster: K. Krebs (Germany)	
A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells	P74
Poster: M. Van Loenen (Netherlands)	
Genetic engineering of T cells for increased homing to the tumor site	P75
Poster: M. Idorn (Denmark)	

Friday 14 March 2014

Plenary Session: Adoptive Cell Therapy

08:30 - 10:00

Auditorium

Chair: F. Marincola (Qatar)

- | | | |
|-------|--|-----|
| 08:30 | KEYNOTE LECTURE: Basic concept for the understanding of cancer mediated immune rejection
Speaker: F. Marincola (Qatar) | S75 |
| 09:00 | Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes
Speaker: I.M. Svane (Denmark) | S76 |
| 09:20 | Autologous cellular immunotherapy for prostate cancer
Speaker: G. Perez de Lema (USA) | |
| 09:40 | Proffered Paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing
Speaker: S. Reuther (Germany) | S77 |
| 09:50 | Proffered Paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology
Speaker: L. Jahn (Netherlands) | S78 |

Plenary Session: Engineered T Cell Therapy

10:30 - 12:00

Auditorium

Chair: A. Shen (USA)
 Chair: R. Hawkins (United Kingdom)

- | | | |
|-------|--|-----|
| 10:30 | CAR strategies in solid tumours
Speaker: C. Rossig, ` (Germany) | S79 |
| 11:00 | Prolongation of T cell response by OX40 co-signalling CARS
Speaker: H. Abken (Germany) | S80 |

- 11:20 **Proffered Paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy** S81
 Speaker: S. Kobold (Germany)
- 11:40 **Proffered Paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer** S82
 Speaker: Z. Liu (United Kingdom)

Plenary Session: Closing Remarks

12:00 - 12:30

Auditorium

Closing remarks

Speaker: V. Nussler (Germany)

Poster Award Presentation

Speaker: H. Hendriks (Netherlands)